NAUT
Nautilus Biotechnolgy, Inc. (NAUT) Risks & Opportunities Analysis (2026)
Overall Score
Financial Distress Liquidity Risk
Very strong near-term liquidity with a current ratio of 10.14x and cash ratio of 1.52x.
Net debt remains low relative to EBITDA, with netDebtToEBITDATTM at -0.27x.
Net current asset value is positive at $55.2M, supporting balance-sheet resilience.
Profitability Cash Burn Risk
TTM margins remain deeply negative, with gross margin at -9.2% and net margin at -297.5%.
Operating cash flow and free cash flow are both negative, with freeCashFlowYieldTTM at -42.4%.
Returns on capital remain weak, including ROIC at -39.5% and ROE at -37.6%.
Valuation Dilution Risk
Valuation remains difficult to anchor on earnings or cash flow because TTM earnings and free cash flow are negative.
Price-to-book is 0.93x and price-to-sales is extremely elevated at 644.18x, reflecting a highly speculative revenue base.
Stock-based compensation remains meaningful at 28.9% of revenue, which can pressure per-share economics.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Nautilus Biotechnolgy, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

